Abstract 4701
Background
Non-squamous non-small cell lung cancer (NSCLC) accounts for majority of lung cancer, the second most common cancer in US. Combination of checkpoint inhibitors and chemotherapy has become a fundamental paradigm shift in the first-line treatment of advanced lung cancer. We conducted a combined analysis of randomized controlled trials (RCT) to determine the risk of treatment-related adverse events (TRAE) and treatment discontinuation due to TRAE.
Methods
PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019 were queried. RCTs of first-line chemotherapy +/- immunotherapy in patients with advanced non-squamous NSCLC were incorporated. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) and risk difference (RD) with 95% confidence interval (CI). Random effects model was applied.
Results
A total of 2785 patients with advanced non-squamous NSCLC from 5 RCTs were included. The study arm used standard chemotherapy regimens in combination with pembrolizumab or atezolizumab while control arm used only standard chemotherapy regimens. The randomization ratio was 2:1 in IMpower-130 and Keynote-189 studies and 1:1 in other studies. The pooled RR of any-grade TRAE was 1.02 (95% CI: 0.99 –1.04, P = 0.20) and RR of high-grade TRAE was significant at 1.20 (95% CI: 1.07 –1.34, P = 0.002). Treatment-related deaths were 58 (3.57%) in study arm vs 31 (2.66%) in control arm. The pooled RR was not statistically significant at 1.26 (95% CI: 0.81 –1.95, P = 0.31) and RD was 0.01 (95% CI: - 0.00 – 0.02, P = 0.08). Treatment discontinuation due to TRAE was noted in 440 (27.14%) vs 235 (20.19%) in control group with RR of 1.35 (95% CI: 1.15 –1.59, P = 0.0003) and RD of 0.07 (95% CI: 0.03 – 0.11, P = 0.001).
Conclusions
Patients on upfront combined chemoimmunotherapy experienced high-grade TRAE, ultimately leading to treatment discontinuation. Yet, there were no significant increase in the risk of treatment related deaths due to TRAE, compared to standard chemotherapy. Pre-emptive measures with proper supportive care may enhance patients’ quality of life and compliance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kyaw Zin Thein.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract